AU2006318550A1 - Intraocular pressure-regulated early genes and uses thereof - Google Patents

Intraocular pressure-regulated early genes and uses thereof Download PDF

Info

Publication number
AU2006318550A1
AU2006318550A1 AU2006318550A AU2006318550A AU2006318550A1 AU 2006318550 A1 AU2006318550 A1 AU 2006318550A1 AU 2006318550 A AU2006318550 A AU 2006318550A AU 2006318550 A AU2006318550 A AU 2006318550A AU 2006318550 A1 AU2006318550 A1 AU 2006318550A1
Authority
AU
Australia
Prior art keywords
expression
regulated
gene
ipreg
ipregs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006318550A
Other languages
English (en)
Inventor
H. Uri Saragovi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University filed Critical McGill University
Publication of AU2006318550A1 publication Critical patent/AU2006318550A1/en
Priority to AU2012202220A priority Critical patent/AU2012202220B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/168—Glaucoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2006318550A 2005-11-22 2006-11-22 Intraocular pressure-regulated early genes and uses thereof Abandoned AU2006318550A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012202220A AU2012202220B2 (en) 2005-11-22 2012-04-17 Intraocular pressure-regulated early genes and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73957005P 2005-11-22 2005-11-22
US60/739,570 2005-11-22
PCT/US2006/045169 WO2007062101A2 (en) 2005-11-22 2006-11-22 Intraocular pressure-regulated early genes and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012202220A Division AU2012202220B2 (en) 2005-11-22 2012-04-17 Intraocular pressure-regulated early genes and uses thereof

Publications (1)

Publication Number Publication Date
AU2006318550A1 true AU2006318550A1 (en) 2007-05-31

Family

ID=38067890

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006318550A Abandoned AU2006318550A1 (en) 2005-11-22 2006-11-22 Intraocular pressure-regulated early genes and uses thereof

Country Status (7)

Country Link
US (1) US8563520B2 (cg-RX-API-DMAC7.html)
EP (1) EP1957986B1 (cg-RX-API-DMAC7.html)
JP (1) JP5249774B2 (cg-RX-API-DMAC7.html)
CN (1) CN101360999B (cg-RX-API-DMAC7.html)
AU (1) AU2006318550A1 (cg-RX-API-DMAC7.html)
CA (1) CA2630668C (cg-RX-API-DMAC7.html)
WO (1) WO2007062101A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0634001Y2 (ja) 1989-02-02 1994-09-07 石川島播磨重工業株式会社 水平対向型幅プレスの金型取付装置
AU2006318550A1 (en) * 2005-11-22 2007-05-31 Mcgill University Intraocular pressure-regulated early genes and uses thereof
US8648169B2 (en) 2006-12-05 2014-02-11 The Royal Institution For The Advancement Of Learning/Mcgill University Methods of use of Trk receptor modulators
WO2010118340A1 (en) * 2009-04-09 2010-10-14 University Of Medicine And Dentistry Of New Jersey Treatment of cutaneous hemangioma
CN102210851A (zh) * 2011-05-31 2011-10-12 中国人民解放军第三军医大学第一附属医院 人αB-晶体蛋白在制备保护视网膜神经节细胞的药物中的应用
US20140228299A1 (en) * 2011-09-20 2014-08-14 National University Corporation Tokyo Medical And Dental University Prophylactic and therapeutic agent for neurological diseases using lipoproteins and prophylactic and therapeutic method for neurological diseases
EP3140422A1 (en) * 2014-05-03 2017-03-15 The Regents of The University of California Methods of identifying biomarkers associated with or causative of the progression of disease, in particular for use in prognosticating primary open angle glaucoma
US20180021404A1 (en) * 2015-02-20 2018-01-25 The Regents Of The University Of California Methods and compositions for treating glaucoma
JP7033840B2 (ja) * 2016-06-17 2022-03-11 ユーロイミューン・メディツィニシェ・ラボルディアグノシュティカ・アクチエンゲゼルシャフト 神経自己免疫疾患の診断
CN106434933A (zh) * 2016-10-11 2017-02-22 青岛大学 Crybb2基因在制备检测先天性白内障制品中的应用
US12606868B2 (en) 2020-02-24 2026-04-21 The Board Of Regents Of The University Of Texas System Molecular biomarkers and targets for Fuchs' endothelial corneal dystrophy and glaucoma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
CN2237430Y (zh) * 1995-07-20 1996-10-16 北京市橡胶制品设计研究院 青光眼房水引流盘
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US6482854B1 (en) * 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment
DE10305212A1 (de) * 2003-02-07 2004-08-19 Florian Prof. Dr.med. Lang Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉a基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途
DE602005012812D1 (de) * 2005-06-13 2009-04-02 Primm Srl Heterodimere Peptide mit NGF Aktivität und deren Verwendung zur Behandlung von neurodegenerativen Krankheiten
AU2006318550A1 (en) * 2005-11-22 2007-05-31 Mcgill University Intraocular pressure-regulated early genes and uses thereof
EP1921087A1 (en) 2006-11-10 2008-05-14 Primm S.R.L. Process for the preparation of cyclic peptides

Also Published As

Publication number Publication date
CA2630668A1 (en) 2007-05-31
CN101360999B (zh) 2013-07-17
JP5249774B2 (ja) 2013-07-31
US8563520B2 (en) 2013-10-22
WO2007062101A2 (en) 2007-05-31
EP1957986B1 (en) 2017-05-24
EP1957986A2 (en) 2008-08-20
WO2007062101A3 (en) 2008-03-06
CA2630668C (en) 2016-07-12
CN101360999A (zh) 2009-02-04
US20080305103A1 (en) 2008-12-11
JP2009519232A (ja) 2009-05-14

Similar Documents

Publication Publication Date Title
US8563520B2 (en) Treatment of ocular disease with inhibitors of alpha2 macroglobulin protein
Xie et al. Intranasal administration of recombinant Netrin-1 attenuates neuronal apoptosis by activating DCC/APPL-1/AKT signaling pathway after subarachnoid hemorrhage in rats
US20220105059A1 (en) Method of treating or preventing neurodegeneration
US10941212B2 (en) Compositions and methods for detecting, treating and preventing diseases and disorders
US11129879B2 (en) Methods for the treatment of neurological disorders and diseases using FNDC5
EP1418834A2 (en) Methods for diagnosing and treating alzheimer's disease and parkinson's disease
Wei et al. Targeting the Dvl-1/β-arrestin2/JNK3 interaction disrupts Wnt5a-JNK3 signaling and protects hippocampal CA1 neurons during cerebral ischemia reperfusion
US20030162706A1 (en) Angiogenesis modulating proteins
Liu et al. Opticin Ameliorates Hypoxia-Induced Retinal Angiogenesis by Suppression of Integrin α2-I Domain–Collagen Complex Formation and RhoA/ROCK1 Signaling
AU2012202220A1 (en) Intraocular pressure-regulated early genes and uses thereof
JP2005518443A (ja) 脳虚血または脳損傷を予防または治療する方法
US10369191B2 (en) Modulation of epigenetic stress response
US9878021B2 (en) Compositions and methods for treatment of retinal degenerative diseases
US20120232121A1 (en) Use of sarcoplasmic ca2+-atpase type 2 protein for diagnosing and treating learning or mental disorders
Sahin Neurotrophic Actions of Leptin in Hippocampal Synaptogenesis During Development
WO2025191291A1 (en) Methods for the prevention or treatment of erectile dysfunction (ed) by administering slpis (secretory leukocyte protease inhibitors)
JP2025506679A (ja) Fndc5又はその生物学的に活性な断片を調節する薬剤を使用する、病理学的アルファ-シヌクレインを低下させるための方法
WO2015168786A1 (en) Method for decreasing retinal ganglion cells degeneration
Icton Probing the interaction between huntingtin and NMDA receptors
US20070282017A1 (en) Methods and compositions for treating and preventing neurologic disorders
Gil et al. Anti-Inflammatory Mechanisms of the

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted